LARODOPA
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARODOPA is an oral small-molecule tablet approved in 1970 as an NDA product by Roche. The drug's specific mechanism of action, pharmacologic class, and indications are not publicly detailed in available data. This legacy product represents a foundational therapeutic from the pre-modern drug development era.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30/100), brand teams are likely focused on defensive positioning and transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARODOPA currently has zero linked job openings, reflecting its mature lifecycle status and approaching loss of exclusivity. Career opportunities are concentrated in commercial roles focused on market defense and profitable managed decline rather than growth or innovation.
Brand ManagerSales Representative
Worked on LARODOPA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.